Hiroshi Ureshino

Saga, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 107 publications

Predictors of treatment-free remission (TFR) and second TFR attempts in chronic myeloid leukemia

Predictors of treatment-free remission (TFR) and second TFR attempts in chronic myeloid leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 30, 2026

Treatment-Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure.

Treatment-Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure.

Journal: Cancer science
Published: July 22, 2026

Do FLT3 and KIR3DL1 converge on a common immune surveillance axis in treatment-free remission of chronic myeloid leukemia?

Do FLT3 and KIR3DL1 converge on a common immune surveillance axis in treatment-free remission of chronic myeloid leukemia?

Journal: Leukemia
Published: July 07, 2026

Clonal dynamics and therapeutic pressure in myeloproliferative neoplasm with concomitant chronic myeloid leukemia: Potential implications of JAK2-directed therapy and additional mutations.

Clonal dynamics and therapeutic pressure in myeloproliferative neoplasm with concomitant chronic myeloid leukemia: Potential implications of JAK2-directed therapy and additional mutations.

Journal: Leukemia
Published: March 30, 2026

Dynamic improvement of the treatment-free remission prognostic score by prolonging MR4 duration in chronic myeloid leukaemia.

Dynamic improvement of the treatment-free remission prognostic score by prolonging MR4 duration in chronic myeloid leukaemia.

Journal: British journal of haematology
Published: March 11, 2026

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Journal: Blood cancer journal
Published: February 14, 2026

Potential impact of NK-cell education on interferon efficacy in the ENDURE trial.

Potential impact of NK-cell education on interferon efficacy in the ENDURE trial.

Journal: Leukemia
Published: January 18, 2026

Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells.

Platinum TALEN-mediated nonviral gene editing facilitates clinical-scale production of cancer antigen-reactive T cells.

Journal: Cytotherapy
Published: January 17, 2026

Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia.

Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia.

Journal: Expert review of hematology
Published: January 07, 2026

Peripheral Blood Neutrophil Maturation as a Practical Predictor of Treatment-Free Remission in CML.

Peripheral Blood Neutrophil Maturation as a Practical Predictor of Treatment-Free Remission in CML.

Journal: International journal of laboratory hematology
Published: October 09, 2025

Longer-than-expected survival in TP53-mutated MDS with der(5;19)(p10;q10): lessons from three cases.

Longer-than-expected survival in TP53-mutated MDS with der(5;19)(p10;q10): lessons from three cases.

Journal: International journal of hematology
Published: October 03, 2025

Tumor Inflammation-associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy in a Patient with High-grade B-cell Lymphoma.

Tumor Inflammation-associated Neurotoxicity Following CD19-targeted Chimeric Antigen Receptor T-cell Therapy in a Patient with High-grade B-cell Lymphoma.

Journal: Internal medicine (Tokyo, Japan)
Published: October 01, 2025
Showing 1-12 of 107

Last Updated: 09/26/2026